Immunovant, Inc.
IMVT · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | -1.69 | -0.46 | -0.22 |
| FCF Yield | -14.54% | -4.92% | -9.87% | -17.60% |
| EV / EBITDA | -4.29 | -13.82 | -7.37 | -0.72 |
| Quality | ||||
| ROIC | -62.06% | -43.80% | -57.27% | -33.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.83 | 0.89 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -75.52% | -13.91% | -77.11% | -27.33% |
| Safety | ||||
| Net Debt / EBITDA | 1.63 | 2.35 | 1.80 | 3.15 |
| Interest Coverage | 0.00 | 0.00 | -16.69 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |